Eradication of tumor cells after injection into immunized hosts compared with the eradication of tumor cells after transfer of immune peritoneal exudates into tumor-bearing recipients

Otter, W. Den; Groot, Jan Willem de; Dullens, H. F. J.

doi:10.1007/bf00199234

Cited by 1 publication

(1 citation statement)

References 16 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This tumor is responding to immunotherapy, i.e., treatment with local low doses of IL-2 [26]. Further, immunization of mice with irradiated SL2 cells resulted in eradication of later injected, viable SL2 cells [27]. In this study we found that M8013 mammary carcinoma is responding to IL-2 treatment alone (Table 1B), indicating that this tumor is also immunogenic.…”

Section: Discussionmentioning

confidence: 66%

Anti-tumor effects of local irradiation in combination with peritumoral administration of low doses of recombinant interleukin-2 (rIL-2)

Jürgenliemk-Schulz¹,

Renes

Rutgers³

et al. 1997

Radiat. Oncol. Investig.

Self Cite

View full text Add to dashboard Cite

The aim of this work was to improve radiotherapy results by immune stimulation. We tested the effects of a combination of radio‐ and immunotherapy, i.e., local low dose recombinant interleukin‐2 (rIL‐2) treatment, in two murine tumor models. Syngeneic tumors (SL2 lymphoma or M8013 mammary carcinoma) were induced subcutaneously on one or both flanks of mice. Irradiation was given either as a single dose (20 Gy) or fractionated (25 Gy) in 2 weeks. One or two cycles of rIL‐2 were given concurrent with or subsequent to radiotherapy. One cycle of rIL‐2 consisted of peritumoral injections administered on 5 consecutive days. Treatment effects were measured in terms of local tumor response and disease‐free survival (DFS). The combined treatment modality was significantly better than treatment with either irradiation alone or rIL‐2 alone. When tumors were inoculated on both flanks of the mice, combined radioimmunotherapy of one of the tumors also resulted in regression of the contralateral untreated tumor, indicating that a systemic anti‐tumor immune reaction was induced. Additional rIL‐2 injections did not enhance radiation toxicity. In conclusion supplementing irradiation with locally administered low doses of rIL‐2 results in better local anti‐tumor responses and DFS rates than either treatment alone without enhanced treatment toxicity. Furthermore, the local treatment induces a systemic anti‐tumor reaction, influencing the growth patterns of a second, untreated tumor. Radiat. Oncol. Invest. 5:54–61, 1997. © 1997 Wiley‐Liss, Inc.

show abstract

Section: Discussionmentioning

confidence: 66%